Why the study?
Whether mineralocorticoid receptor signaling contributes to altered cardiac metabolism and metabolic inflexibility in obesity is unclear.
Does spironolactone improve cardiac glucose uptake and prevent cardiac metabolic remodeling in obese Ossabaw swine?
Population
Lean and obese Ossabaw swine
Comparison
Obese swine treated with spironolactone (25 mg/d) vs untreated obese swine vs lean swine
Design
Preclinical animal study
Key result
Chronic mineralocorticoid receptor blockade with spironolactone prevented the reduction in myocardial glucose uptake and metabolic remodeling in obese Ossabaw swine.
Authors
Loading...
Whether MR signaling drives cardiac metabolic inflexibility in obesity remains unclear; this leaves open whether MR antagonists could restore myocardial glucose oxidation.
Does spironolactone improve cardiac glucose uptake and prevent cardiac metabolic remodeling in obese Ossabaw swine?
In an obese swine model, mineralocorticoid receptor blockade with spironolactone prevents cardiac metabolic inflexibility and transcriptomic changes associated with cardiomyopathy.
Bender et al. (2026) studied Obesity-associated cardiac metabolic remodeling. Spironolactone vs. Lean swine and untreated obese swine was evaluated on Myocardial glucose uptake and metabolic remodeling. Chronic mineralocorticoid receptor blockade with spironolactone prevented the reduction in myocardial glucose uptake and metabolic remodeling in obese Ossabaw swine.